Population Pharmacokinetic Modeling for Ceftazidime‐Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older

医学 肾功能 阿维巴坦 人口 头孢他啶 头孢他啶/阿维巴坦 肺炎 药代动力学 肾脏疾病 细菌性肺炎 内科学 外科 铜绿假单胞菌 遗传学 环境卫生 生物 细菌
作者
Richard C. Franzese,Todd Riccobene,Timothy J. Carrothers,Manoli Vourvahis,Erica Winter,Mark Lovern,Lynn McFadyen
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:113 (1): 182-195 被引量:2
标识
DOI:10.1002/cpt.2764
摘要

Ceftazidime‐avibactam is a novel β‐lactam/β‐lactamase inhibitor combination developed to treat serious Gram‐negative bacterial infections; approved indications include complicated urinary tract infection, complicated intra‐abdominal infection, and hospital‐acquired pneumonia including ventilator‐associated pneumonia in patients ≥ 3 months old. Because of the predominantly renal clearance of ceftazidime and avibactam, dose adjustments (reductions) are required for patients with estimated creatinine clearance (CrCL) ≤ 50 mL/min. We describe the application of combined adult and pediatric population pharmacokinetic models in developing ceftazidime‐avibactam dose recommendations for pediatric patients ≥ 2 to < 18 years old with body surface area‐normalized CrCL ≤ 50 mL/min/1.73 m 2 , including moderate, severe, or very severe renal impairment, or end‐stage renal disease requiring hemodialysis, and for patients ≥ 3 months to < 2 years old with mild, moderate, or severe renal impairment. Models included allometric scaling for all subjects and simulations (1,000 subjects per age group, renal function group, and indication) were performed nonparametrically using post hoc random effects. Doses were selected based on simulated pediatric patients achieving steady‐state exposures similar to adults and high probability of target attainment (using a simultaneous joint target for both ceftazidime and avibactam). Because there were few children with renal impairment in the ceftazidime‐avibactam clinical trials, selected pediatric doses were guided by extrapolation and matching of adult exposures associated with efficacy and within established safety margins. The recommended doses for pediatric patients with estimated CrCL ≤ 50 mL/min/1.73 m 2 use equivalent adjustments in dose quantity and/or administration interval (vs. the corresponding age group with normal renal function) as those for adults.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
tough_cookie完成签到 ,获得积分10
2秒前
彩钢房完成签到,获得积分10
3秒前
MeSs完成签到 ,获得积分10
4秒前
toxikon完成签到,获得积分10
5秒前
一点通完成签到,获得积分10
5秒前
Lei完成签到,获得积分10
6秒前
6秒前
6秒前
常若冰完成签到,获得积分10
6秒前
纯真的元风完成签到,获得积分10
7秒前
哇哈哈哈完成签到,获得积分10
7秒前
清秋1001完成签到 ,获得积分10
8秒前
qq完成签到,获得积分10
9秒前
荒野风发布了新的文献求助10
10秒前
Zxx发布了新的文献求助10
11秒前
12秒前
12秒前
确幸完成签到 ,获得积分10
12秒前
苒苒完成签到,获得积分10
12秒前
13秒前
酷波er应助c123采纳,获得10
13秒前
TIAOTIAO完成签到,获得积分10
15秒前
未晚完成签到 ,获得积分10
15秒前
16秒前
16秒前
天天快乐应助qinglinglie采纳,获得10
16秒前
自由老头应助荒野风采纳,获得10
16秒前
本末倒纸发布了新的文献求助10
17秒前
17秒前
甜蜜老虎完成签到,获得积分10
17秒前
脑洞疼应助帅气的蚊子采纳,获得10
18秒前
你好完成签到 ,获得积分10
19秒前
20秒前
20秒前
XZZ完成签到 ,获得积分10
20秒前
21秒前
22秒前
小阿飞完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066